Pure Global AI
Disease / condition

Melanoma clinical trials

Free access to 716 studies10+ countriesUpdated daily120 recruiting
VerifiedClinicalTrials.gov · WHO ICTRP · regional registries
716
Total trials
10+
Countries
10+
Sponsors
120
Recruiting
By phase
N/A204
Phase 2197
Phase 1136
Early Phase 171
Phase 365
By status
Completed315
Recruiting120
Terminated93
Not yet recruit...64
Unknown47
Top countries
United States of America302
China42
France34
Australia33
United Kingdom22
Top sponsors
Bristol-Myers Squi...61
M.D. Anderson Canc...34
Memorial Sloan Ket...18
Merck Sharp & Dohm...14
Novartis Pharmaceu...14
Recent trials
Latest clinical trials for Melanoma
Etude rétrospective Monocentrique MATRIX
Centre Hospitalier Universitai... · France
NCT06415929Completed
LATe TreatmENT Related Toxicity in Melanoma (LATENT)
Royal Marsden NHS Foundation T... · United Kingdom
NCT06414343Not yet recr...
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
University of Utah · United States of America
NCT06365619Not yet recr...
Phase
Phase 2
Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure
Hunan Cancer Hospital
NCT06327698Not yet recr...
Phase
Phase 2
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma
Regeneron Pharmaceuticals
NCT06246916Not yet recr...
Phase
Phase 3
ctDNA for Early Detection of Recurrence in Melanoma
Herlev and Gentofte Hospital · Denmark
NCT06246227Recruitment ...
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
The Netherlands Cancer Institu... · Netherlands
NCT06240143Not yet recr...
Phase
Phase 1/2
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
Yana Najjar · United States of America
NCT06216938Recruiting
Phase
Phase 1
Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma
Xijing Hospital
NCT06212388Not yet recr...
Phase
Phase 1
Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients
University Hospital, Grenoble
NCT06154668Not yet recr...
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Bristol-Myers Squibb · Argentina,Chile,Greece,Italy,Spain,United States of America
NCT06101134Not yet recr...
Phase
Phase 2
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
Sandoz
NCT06153238Not yet recr...
Phase
Phase 1
A Study of IBI363 in Subjects With Advanced Melanoma
Innovent Biologics (Suzhou) Co... · China
NCT06081920Recruiting
Phase
Phase 1/2
Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response
Erasmus Medical Center · Netherlands
NCT06116461Recruiting
Phase
Phase 4
Untitled Trial
Amgen Inc. · North America;South America;Europe;Africa;Asia
jRCT2031230360Not yet recr...
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Amgen · Canada,Georgia,Lithuania,Spain,United States of America
NCT06054555Recruiting
Phase
Phase 3
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Shanghai Kechow Pharma, Inc. · China
NCT06008106Not yet recr...
Phase
Phase 3
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
Peking University Cancer Hospi...
NCT05983237Not yet recr...
Phase
Phase 1/2
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Merck Sharp & Dohme LLC · Australia
NCT05933577Recruiting
Phase
Phase 3
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
Memorial Sloan Kettering Cance... · United States of America
NCT05912244Recruiting
Phase
Phase 2
View all 716 trials →
About this profile

Access comprehensive clinical trial information for Melanoma through Pure Global AI's free database. This collection includes 716 clinical trials across multiple phases including N/A, Phase 2, Phase 1. Currently, 120 trials are actively recruiting participants.

Research for Melanoma is being conducted in United States of America, China, France and 7+ other countries. Leading sponsors include Bristol-Myers Squibb and M.D. Anderson Cancer Center. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.

Pure Global AI provides free access to 716 clinical trials studying Melanoma, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.

The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.

Top research sponsors include Bristol-Myers Squibb, M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, among others.